by guojie | Mar 31, 2021 | Insights
Author: Ginger Ding Following PD-(L)1, high-end players have quickly joined the race to develop the new star T cell immunoreceptors with immunoglobulin and ITIM domain (TIGIT). Roche, BMS, Merck and other international pharmaceutical companies have all entered.... by guojie | Mar 31, 2021 | Insights
Author: Dr. Ginger Ding As a target of extensive research, NLRP3 is the culprit behind a long list of inflammation-related diseases including diabetes, gout, Alzheimer’s disease, NASH, inflammatory bowel disease, and atherosclerosis. However, NLRP3 does not... by guojie | Mar 31, 2021 | Insights
Author: HE Sheng Recently, the Hurun Research Institute released their list of “Hurun’s 2020 Top Chinese 500 Private Enterprises”, ranked according to the companies’ market value or valuation. The market value of listed companies is calculated based on closing... by guojie | Mar 31, 2021 | Insights
Author: Ginger Ding At the end of 2020, as IPOs and China cross-border transactions reached a record high, Overland Pharmaceuticals announced joint ventures with ADC Therapeutics and Allogene. This announcement occurred just a week after Overland’s debut. The... by guojie | Mar 31, 2021 | Insights
Author: HE Sheng In China, licensing in has become a key link in the new drug research and development industry chain. Licensing is when one company gives another company permission for a specific period of time to manufacture its product in return for an...